CAPSTONE: Phase III Confirmatory Assessment Protocol: rVA576 Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH)

Trial Profile

CAPSTONE: Phase III Confirmatory Assessment Protocol: rVA576 Safety and Efficacy in Three-Part, Two-Arm, Randomised Open Label Evaluation in patients with Paroxysmal Nocturnal Haemoglobinuria (PNH)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Nomacopan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Acronyms CAPSTONE
  • Sponsors Akari Therapeutics
  • Most Recent Events

    • 30 Sep 2018 Status changed from planning to recruiting, according to an Akari Therapeutics media release.
    • 21 Mar 2018 According to an Akari Therapeutics media release, the company received regulatory clearance in Europe to open first clinical trial site and looking forward to the opening of the first clinical site by the end of March.
    • 06 Feb 2018 According to an Akari Therapeutics media release, the trial is anticipated to begin by the end of first quarter 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top